FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132303718> ?p ?o ?g. }

• W3132303718 endingPage "15" @default.
• W3132303718 startingPage "PS14" @default.
• W3132303718 abstract "Abstract Background: Human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) is associated with increased clinical and economic burden. Patients with brain metastases (BM) have significantly worse outcomes, however, limited data exist evaluating healthcare resource utilization (HCRU) among HER2+ MBC patients with BM. Objective: To describe treatment patterns and HCRU among HER2+ MBC patients with or without brain metastases who received HER2-targeted therapy using retrospective claims data. Methods: Data obtained from the IBM Watson HealthTM MarketScan commercial claims and Medicare Supplemental database from July 2012 to December 2018 were used to evaluate HER2+ MBC patients. We describe demographic and clinical characteristics, treatment patterns by line of therapy (LOT) by the presence or absence of BM, and HCRU. The first metastatic diagnosis date was the study initiation (index) date. HCRU outcomes per patient per year (PPPY) in the follow-up period after metastatic diagnosis were measured overall and by BM vs non-BM. These HCRU outcomes included inpatient (IP) services, total length of stay (LOS), emergency room (ER) services, and outpatient (OP) services. Results: A total of 4,509 patients were included. One-hundred and three (2.3%) patients had BM and 4,406 had no evidence of BM at index. However, 590 (13.1%) developed BM after study initiation. The mean age at index was 53.7 years. Median follow-up time was 23.2 months overall (22.1 months for patients with BM at index and 23.2 months for patients without BM at index). Median time on treatment (months) was 7.6, 7.2, and 6.2 for first line (1L), 2L, and 3L, respectively. Trastuzumab-based regimens were most used across all LOTs. Trastuzumab emtansine (T-DM1) use in 1L was 0.9% (2.4% in BM and 0.9% in non-BM patients). T-DM1 use increased in 2L (9.7%) and 3L (13.0%) and differed for BM vs non-BM patients in 2L (22.6% vs 7.7%) and 3L (25% vs 10.1%). Overall, lapatinib use ranged from 1.6% (1L) to 8.3% (3L). BM patients had a higher frequency of lapatinib use compared to non-BM patients (1L: 11.8% vs 1.2%; 2L: 20.5% vs 1.8%; 3L: 21.2% vs 5.1%). The mean number of IP services PPPY was 0.6 and higher for BM patients (1.2 vs 0.5). The mean total LOS PPPY was 2.7 days and BM patients had higher total LOS (8.6 vs 2.6 days) compared to non-BM patients. The average number of ER visits PPPY was 1.2 and BM patients had higher frequency of ER visits (2.5 vs 1.2). The mean number of OP services PPPY was 57.1; however, no obvious difference was observed between BM and non-BM patients (62.1 vs 56.9). Conclusions: Among HER2+ MBC patients, there is significantly higher HCRU among BM patients compared to patients without BM. This highlights the need for more effective systemic therapies that improve outcomes and reduce disease and healthcare system burden for HER2+ MBC patients, particularly those with BM. Citation Format: Chiemeka Ike, Naomi Schwartz, Andy Surinach, Yutong Liu, Kendra DeBusk, Thomas Walters. Real world treatment patterns and healthcare resource utilization among HER2+ metastatic breast cancer patients with and without brain metastases: A retrospective cohort study [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS14-15." @default.
• W3132303718 created "2021-03-01" @default.
• W3132303718 creator A5009290511 @default.
• W3132303718 creator A5047262526 @default.
• W3132303718 creator A5050118261 @default.
• W3132303718 creator A5061672164 @default.
• W3132303718 creator A5063684760 @default.
• W3132303718 creator A5087320027 @default.
• W3132303718 date "2021-02-15" @default.
• W3132303718 modified "2023-10-02" @default.
• W3132303718 title "Abstract PS14-15: Real world treatment patterns and healthcare resource utilization among HER2+ metastatic breast cancer patients with and without brain metastases: A retrospective cohort study" @default.
• W3132303718 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps14-15" @default.
• W3132303718 hasPublicationYear "2021" @default.
• W3132303718 type Work @default.
• W3132303718 sameAs 3132303718 @default.
• W3132303718 citedByCount "0" @default.
• W3132303718 crossrefType "journal-article" @default.
• W3132303718 hasAuthorship W3132303718A5009290511 @default.
• W3132303718 hasAuthorship W3132303718A5047262526 @default.
• W3132303718 hasAuthorship W3132303718A5050118261 @default.
• W3132303718 hasAuthorship W3132303718A5061672164 @default.
• W3132303718 hasAuthorship W3132303718A5063684760 @default.
• W3132303718 hasAuthorship W3132303718A5087320027 @default.
• W3132303718 hasConcept C121608353 @default.
• W3132303718 hasConcept C126322002 @default.
• W3132303718 hasConcept C143998085 @default.
• W3132303718 hasConcept C167135981 @default.
• W3132303718 hasConcept C2775930923 @default.
• W3132303718 hasConcept C2778164965 @default.
• W3132303718 hasConcept C2779013556 @default.
• W3132303718 hasConcept C530470458 @default.
• W3132303718 hasConcept C71924100 @default.
• W3132303718 hasConcept C72563966 @default.
• W3132303718 hasConceptScore W3132303718C121608353 @default.
• W3132303718 hasConceptScore W3132303718C126322002 @default.
• W3132303718 hasConceptScore W3132303718C143998085 @default.
• W3132303718 hasConceptScore W3132303718C167135981 @default.
• W3132303718 hasConceptScore W3132303718C2775930923 @default.
• W3132303718 hasConceptScore W3132303718C2778164965 @default.
• W3132303718 hasConceptScore W3132303718C2779013556 @default.
• W3132303718 hasConceptScore W3132303718C530470458 @default.
• W3132303718 hasConceptScore W3132303718C71924100 @default.
• W3132303718 hasConceptScore W3132303718C72563966 @default.
• W3132303718 hasIssue "4_Supplement" @default.
• W3132303718 hasLocation W31323037181 @default.
• W3132303718 hasOpenAccess W3132303718 @default.
• W3132303718 hasPrimaryLocation W31323037181 @default.
• W3132303718 hasRelatedWork W2113769490 @default.
• W3132303718 hasRelatedWork W2224319365 @default.
• W3132303718 hasRelatedWork W2272726339 @default.
• W3132303718 hasRelatedWork W2603750384 @default.
• W3132303718 hasRelatedWork W3091780641 @default.
• W3132303718 hasRelatedWork W3114415956 @default.
• W3132303718 hasRelatedWork W3181412252 @default.
• W3132303718 hasRelatedWork W3213705426 @default.
• W3132303718 hasRelatedWork W4224327237 @default.
• W3132303718 hasRelatedWork W4249226920 @default.
• W3132303718 hasVolume "81" @default.
• W3132303718 isParatext "false" @default.
• W3132303718 isRetracted "false" @default.
• W3132303718 magId "3132303718" @default.
• W3132303718 workType "article" @default.